[1]
Cuccurullo, V.; Di Stasio, G.D.; Mansi, L. Physiopathological premises to nuclear medicine imaging and therapy of pancreatic neuroendocrine tumours. Curr. Radiopharm., 2019, 12, 98-106.
[2]
Briganti, V.; Cuccurullo, V.; Di Stasio, G.D.; Mansi, L. Gamma emitters in pancreatic endocrine tumors imaging in the PET era: Is there a clinical space for 99mTc-peptides? Curr. Radiopharm., 2019, 12, 156-170.
[3]
Carollo, A.; Papi, S.; Grana, C.M.; Chinol, M. State of the art and recent developments of radiopharmaceuticals for pancreatic neuroendocrine tumors imaging. Curr. Radiopharm., 2019, 12, 107-125.
[4]
Alsadik, S.; Yusuf, S.; Al-Nahhas, A. Peptide receptor radionuclide therapy for pancreatic neuroendocrine tumours. Curr. Radiopharm., 2019, 12, 126-134.
[5]
Zamir, M.A.; Hakim, W.; Yusuf, S.; Thomas, R. Imaging of pancreatic-neuroendocrine tumours: An outline of conventional radiological techniques. Curr. Radiopharm., 2019, 12, 135-155.
[6]
Giovacchini, G.; Giovannini, E.; Riondato, M.; Ciarmiello, A. PET/MR tomographs: A review with technical.; Radiochemical and clinical perspectives. Curr. Radiopharm., 2017, 10, 184-194.
[7]
Mapelli, P.; Piccho, M. PET/MRI in neuroendocrine tumours: Blessings and curses. Curr. Radiopharm., 2019, 12, 96-97.
[8]
Werner, R.A.; Solnes, L.B.; Javadi, M.S.; Weich, A.; Gorin, M.A.; Pienta, K.J.; Higuchi, T.; Buck, A.K.; Pomper, M.G.; Rowe, S.P.; Lapa, C. SSTR-RADS version 1.0 as a reporting system for SSTR PET imaging and selection of potential PRRT candidates: A proposed standardization framework. J. Nucl. Med., 2018, 59, 1085-1091.
[9]
Antoch, G.; Vogt, F.M.; Freudenberg, L.S.; Nazaradeh, F.; Goehde, S.C.; Barkhausen, J. Whole-body dual-modality PET/CT and whole-body MRI for tumor staging in oncology. Jama, 2003, 290, 3199-3206.
[10]
Donati, O.F.; Reiner, C.S.; Hany, T.F.; Fornaro, J.; von Schulthess, G.K. Marincek. B.; Weishaupt, D. 18F-FDG-PET and MRI in patients with malignancies of the liver and pancreas. Accuracy of retrospective multimodality image registration by using the CT-component of PET/CT. Nuklearmedizin, 2010, 49, 106-114.
[11]
Samarin, A.; Burger, C.; Wollenweber, S.D.; Crook, D.W.; Burger, I.A.; Schmid, D.T.; von Schulthess, G.K.; Kuhn, F.P. PET/MR imaging of bone lesions--implications for PET quantification from imperfect attenuation correction. Eur. J. Nucl. Med. Mol. Imaging, 2012, 39, 1154-1160.
[12]
Bodei, L.; Kidd, M.; Modlin, I.M.; Severi, S.; Drozdov, I.; Nicolini, S.; Kwekkeboom, D.J.; Krenning, E.P.; Baum, R.P.; Paganelli, G. Measurement of circulating transcripts and gene cluster analysis predicts and defines therapeutic efficacy of peptide receptor radionuclide therapy (PRRT) in neuroendocrine tumors. Eur. J. Nucl. Med. Mol. Imaging, 2016, 43, 839-851.
Related Books
Frontiers in Clinical Drug Research - Anti-Cancer Agents
NEOPLASIA and FERTILITY
Current Developments in the Detection and Control of Multi Drug Resistance
Breast Cancer: Current Trends in Molecular Research
The Evolution of Radionanotargeting towards Clinical Precision Oncology: A Festschrift in Honor of Kalevi Kairemo
Nanotherapeutics for the Treatment of Hepatocellular Carcinoma
Topics in Anti-Cancer Research
Frontiers in Clinical Drug Research - Anti-Cancer Agents
Modern Cancer Therapies and Traditional Medicine: An Integrative Approach to Combat Cancers
Herbal Medicine: Back to the Future
Article Metrics
24
6
1
1